Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Psychiatry
•
Behavioral Neurology & Neuropsychiatry
•
Geriatric Medicine
•
Dementia
What is your approach to the management of transfusion reactions with lecanemab, both in the immediate setting and with respect to the prevention of reactions with future infusions?
Related Questions
When is it useful to test for multiple amyloid-related biomarkers for patients undergoing work-up for cognitive impairment?
What is your approach to determining eligibility for hospice in persons with Alzheimer's disease?
How do you manage sleep disturbances in patients with Alzheimer’s disease without relying heavily on deliriogenic medications?
How do stroke-risk considerations affect your use of atypical antipsychotics for patients with dementia?
What are the limits and standalone value of volumetric MRI for the preclinical evaluation of dementia?
How do you treat agitation in progressive supranuclear palsy?
What would be your approach to the consideration of the use of antiamyloid monoclonal antibodies for nonamnestic Alzheimer's disease with a positive biomarker for brain amyloid pathology?
How do you counsel non-diabetic patients who wish to start metformin to reduce the risk of developing dementia?
How do you manage problematic disinhibited behaviors in patients with neurocognitive disorders?
What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?
